Analytical Data
-
Gene name
CD8 alpha
- Application
-
Alternative Names
CD8a molecule
-
Species
Others
-
Source
HEK293
-
Tag
C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
ABS50091.1
-
Expression Region
M1-E186
-
Protein Length
Partial
-
Molecular Weight
28-33 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD8 alpha is a crucial component of the immune system, primarily expressed on the surface of cytotoxic T lymphocytes (CTLs). This glycoprotein serves as a co-receptor that enhances T cell receptor (TCR) signaling, playing a pivotal role in the recognition of antigens presented by major histocompatibility complex (MHC) class I molecules. The study of CD8 alpha recombinant proteins has gained significant attention due to their potential applications in immunotherapy and vaccine development. Understanding the structural and functional properties of CD8 alpha can facilitate the design of novel therapeutic agents that enhance T cell responses against tumors and infectious diseases. Moreover, the isolation and characterization of CD8 alpha recombinants enable researchers to explore the mechanisms of T cell activation and modulation, offering insights into immune regulation. Advances in recombinant DNA technology have made it possible to produce CD8 alpha proteins in various biological systems, allowing for detailed biochemical and biophysical studies. These efforts aim not only to elucidate the role of CD8 alpha in T cell activation but also to leverage its functionality in engineered T cell therapies, such as CAR T cells. Overall, the research surrounding CD8 alpha recombinant proteins is pivotal for advancing our understanding of T cell biology and developing innovative therapeutic strategies to combat immunological diseases.
